These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11561779)
1. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Reif S; Kingreen D; Kloft C; Grimm J; Siegert W; Schunack W; Jaehde U Cancer Chemother Pharmacol; 2001 Aug; 48(2):134-40. PubMed ID: 11561779 [TBL] [Abstract][Full Text] [Related]
2. Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters. Mummaneni V; Kaul S; Igwemezie LN; Newell DR; Porter D; Thomas H; Calvert AH; Winograd B; Barbhaiya RH J Pharmacokinet Biopharm; 1996 Aug; 24(4):313-25. PubMed ID: 9044163 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021 [TBL] [Abstract][Full Text] [Related]
5. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232 [TBL] [Abstract][Full Text] [Related]
6. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574 [TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713 [TBL] [Abstract][Full Text] [Related]
8. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients. Li D; Liu L Int J Clin Pharmacol Ther; 2015 Jun; 53(6):474-9. PubMed ID: 25828637 [TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Millward MJ; Newell DR; Mummaneni V; Igwemezie LN; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M Eur J Cancer; 1995 Dec; 31A(13-14):2409-11. PubMed ID: 8652278 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of high-dose etoposide phosphate in man. Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Kreis W; Budman DR; Vinciguerra V; Hock K; Baer J; Ingram R; Schacter LP; Fields SZ Cancer Chemother Pharmacol; 1996; 38(4):378-84. PubMed ID: 8674162 [TBL] [Abstract][Full Text] [Related]
12. Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. de Jong RS; Slijfer EA; Uges DR; Mulder NH; de Vries EG Br J Cancer; 1997; 76(11):1480-3. PubMed ID: 9400945 [TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of etoposide phosphate. Brooks DJ; Srinivas NR; Alberts DS; Thomas T; Igwemzie LM; McKinney LM; Randolph J; Schacter L; Kaul S; Barbhaiya RH Anticancer Drugs; 1995 Oct; 6(5):637-44. PubMed ID: 8845473 [TBL] [Abstract][Full Text] [Related]
14. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. Igwemezie LN; Kaul S; Barbhaiya RH Pharm Res; 1995 Jan; 12(1):117-23. PubMed ID: 7724471 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5. Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892 [TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation. Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of etoposide phosphate plus paclitaxel. Brooks DJ; Alberts DS Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573 [TBL] [Abstract][Full Text] [Related]
20. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]